Spark Therapeutics (ONCE) Announces Earnings Results

Spark Therapeutics (NASDAQ:ONCE) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.73), Morningstar.com reports. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $7.41 million for the quarter, compared to the consensus estimate of $9.53 million.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down $4.27 during midday trading on Wednesday, reaching $50.23. 1,442,600 shares of the company traded hands, compared to its average volume of 751,940. The firm has a market cap of $2,016.80, a P/E ratio of -7.03 and a beta of 3.02. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

ONCE has been the topic of a number of recent research reports. SunTrust Banks lifted their price target on shares of Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. Credit Suisse Group began coverage on shares of Spark Therapeutics in a research note on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 target price on the stock. Cantor Fitzgerald set a $105.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 19th. ValuEngine downgraded shares of Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Raymond James Financial restated a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a research note on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $69.88.

In related news, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total transaction of $356,600.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at approximately $15,333,800. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ONCE. Ameritas Investment Partners Inc. lifted its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Spark Therapeutics during the 2nd quarter worth about $143,000. Public Employees Retirement Association of Colorado acquired a new position in Spark Therapeutics during the 4th quarter worth about $163,000. Aperio Group LLC lifted its position in Spark Therapeutics by 29.2% during the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after buying an additional 898 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Spark Therapeutics during the 3rd quarter worth about $225,000.

COPYRIGHT VIOLATION NOTICE: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2018/02/21/spark-therapeutics-once-announces-earnings-results.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply